Bristol-Myers Squibb

FDA Approval

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Bristol-Myers Squibb

Collaboration

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

Bristol-Myers Squibb

Diversity

Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts

Bristol-Myers Squibb

FDA

FDA Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia

Bristol-Myers Squibb

Healthcare

Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.

Bristol-Myers Squibb

Digital Therapeutics

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

Bristol-Myers Squibb

Bristol-Myers Squibb Announces Update for Patients with Resected High-Risk Melanoma and PD-L1 <1%

Bristol-Myers Squibb

M&A

Bristol-Myers Squibb Provides Update on Pending Merger with Celgene

Bristol-Myers Squibb

M&A

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

Bristol-Myers Squibb

FDA Approval

U.S. Food and Drug Administration Approves Opdivo®(nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer

Bristol-Myers Squibb

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab)

Bristol-Myers Squibb

Collaboration

Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics

Bristol-Myers Squibb

Oncology

Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy

Bristol-Myers Squibb

Strategic Collaboration

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb

Immuno-Oncology

European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Innovation

Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment

Bristol-Myers Squibb